DXCM
DEXCOM INC
$70.22
-1.71%
$27.6B
No data for this timeframe.
Vol
Market Cap$27.6B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders9 funds
Inst. Value$4.8B
Inst. Activity2 buys / 3 sells
Insider Activity0B / 5S
Insider Net $-$448.8K
SEC Reports3
Congressional3 trades
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001093557·Prev Close $71.44
Recent Activity
May 19, 2026
SEC
Two DexCom insiders — Director Bridgette P. Heller and EVP/Chief Legal Officer Michael Jon Brown — executed open-market
CLUSTER — Impact 2/10
May 15, 2026
Insider
Brown Michael Jon sold 1,700 shares
EVP, Chief Legal Officer @ $59.91 ($101.8K)
May 12, 2026
Insider
Heller Bridgette P sold 1,012 shares
Director @ $60.01 ($60.7K)
May 12, 2026
short_volume
Short Volume: DXCM — 56.0% short (1.0M / 1.8M)
Short: 1,018,705 | Exempt: 1,733 | TRF Vol: 1,818,909 | Short Ratio: 56.0% | Off-exchange volume (da
May 8, 2026
Insider
FOLETTA MARK G sold 5,731 shares
Director @ $0.00 ($0.00)
Apr 15, 2026
SEC
Dexcom, Inc. has filed a definitive proxy statement (DEFA14A) for its upcoming annual shareholder meeting. The filing co
DEFA14A — Impact 2/10
Feb 28, 2026
SEC
Three major institutions reduced their positions in Dexcom (DXCM) by a combined $166.3M in Q4 2025, while two others — l
INST-CLUSTER — Impact 6/10
Inst.
NORGES BANK — NEW
7,282,743 shares ($483.4M)
Price Targets
$81.64
+16.3% upside
Buy
Current $70.22
Low $64.00
Median $80.00
High $112.00
25 analysts
$64.00
$112.00
Analyst Ratings
15Strong Buy
17Buy
4Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 18, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| May 18, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| May 18, 2026 | Barclays | MAINTAIN | Underweight → Underweight |
| May 4, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| May 1, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.61 ▲ +0.6% | $0.57 — $0.66 | 26% YoY | 20 |
| Next Q | $0.67 ▼ -0.6% | $0.62 — $0.70 | 10% YoY | 20 |
| Current FY | $2.59 ▲ +3.6% | $2.46 — $2.65 | 24% YoY | 24 |
| Next FY | $3.05 ▲ +1.8% | $2.79 — $3.27 | 18% YoY | 24 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two DexCom insiders — Director Bridgette P. Heller and EVP/Chief Legal Officer Michael Jon Brown — executed open-market
May 19, 2026
NEUTRAL
DEFA14A
2/10
Dexcom, Inc. has filed a definitive proxy statement (DEFA14A) for its upcoming annual shareholder meeting. The filing co
Apr 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $3.3B | — |
| NORGES BANK | $483.4M | NEW |
| MORGAN STANLEY | $336.7M | ADD |
| BANK OF AMERICA CORP | $253.1M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $204.4M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 15, 2026 | Brown Michael | SELL | $101.8K |
| May 12, 2026 | Heller Bridgette | SELL | $60.7K |
| May 8, 2026 | FOLETTA MARK | G | $0.00 |
| May 8, 2026 | ALTMAN STEVEN | G | $0.00 |
| May 8, 2026 | AUGUSTINOS NICHOLAS | G | $0.00 |
Congressional Trades
3 members: 2 buys, 1 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Ro Khanna | D | BUY | $1,001 - $15,000 |
| Michael McCaul | R | SELL | $1,001 - $15,000 |
| John Boozman | R | BUY | $1,001 - $15,000 |
9 institutional holders with $4.8B total value (72,982,412 shares) as of 2025-Q4. Top holders: VANGUARD, NORGES, MORGAN. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 49,074,378 | $3.3B | 67.2% | — |
| 2 | NORGES BANK | 7,282,743 | $483.4M | 10.0% | NEW |
| 3 | MORGAN STANLEY | 5,072,646 | $336.7M | 7.0% | ADD +31.4% |
| 4 | BANK OF AMERICA CORP /DE/ | 3,813,212 | $253.1M | 5.2% | TRIM -25.3% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 3,079,311 | $204.4M | 4.2% | NEW |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 1,444,796 | $95.9M | 2.0% | ADD +71.7% |
| 7 | FMR LLC | 1,298,642 | $86.2M | 1.8% | TRIM -28.7% |
| 8 | TWO SIGMA INVESTMENTS, LP | 1,082,913 | $71.9M | 1.5% | TRIM -27.9% |
| 9 | WELLS FARGO & COMPANY/MN | 833,771 | $55.3M | 1.1% | TRIM -45.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 7,282,743 | — | $483.4M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 5,105,322 | 3,813,212 | -25.3% | $253.1M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 841,564 | 1,444,796 | +71.7% | $95.9M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,501,136 | 1,082,913 | -27.9% | $71.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 1,516,199 | 833,771 | -45.0% | $55.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 3,811,189 | 5,105,322 | +34.0% | $343.5M | 2025-Q3 |
| UBS Group AG | ADD | 2,588,991 | 4,291,922 | +65.8% | $288.8M | 2025-Q3 |
| FMR LLC | TRIM | 2,122,869 | 1,514,609 | -28.7% | $101.9M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 194,787 | 1,501,136 | +670.7% | $101.0M | 2025-Q3 |
| NORGES BANK | EXIT | 5,192,796 | 0 | -100.0% | $0.00 | 2025-Q3 |
| NORGES BANK | NEW | — | 5,192,796 | — | $453.3M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 616,589 | 194,787 | -68.4% | $17.0M | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 8,008,341 | 3,296,123 | -58.8% | $225.1M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 1,231,075 | 1,774,981 | +44.2% | $121.2M | 2025-Q1 |
| FMR LLC | TRIM | 2,562,206 | 1,717,339 | -33.0% | $117.3M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 889,874 | 630,774 | -29.1% | $43.1M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 863,025 | 616,589 | -28.6% | $42.1M | 2025-Q1 |
| NORGES BANK | EXIT | 4,955,208 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 3,406,544 | 8,008,341 | +135.1% | $622.8M | 2024-Q4 |
| MORGAN STANLEY | ADD | 5,255,806 | 6,908,392 | +31.4% | $537.3M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 2,734,155 | — | $183.3M | 2024-Q3 |
12 unique insiders with 5 transactions. Net insider value: -$448.8K ($0.00 bought, $448.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 15, 2026 | Brown Michael Jon | EVP, Chief Legal Officer | SELL | 1,700 | $59.91 | $101.8K |
| May 12, 2026 | Heller Bridgette P | Director | SELL | 1,012 | $60.01 | $60.7K |
| May 8, 2026 | FOLETTA MARK G | Director | G | 5,731 | $0.00 | $0.00 |
| May 8, 2026 | ALTMAN STEVEN R | Director | G | 5,037 | $0.00 | $0.00 |
| May 8, 2026 | AUGUSTINOS NICHOLAS | Director | G | 5,046 | $0.00 | $0.00 |
| May 8, 2026 | Collins Richard Alexander | Director | G | 5,074 | $0.00 | $0.00 |
| Apr 15, 2026 | Brown Michael Jon | EVP, Chief Legal Officer | SELL | 1,700 | $63.04 | $107.2K |
| Mar 16, 2026 | Brown Michael Jon | EVP, Chief Legal Officer | SELL | 1,700 | $64.85 | $110.2K |
| Mar 8, 2026 | Leach Jacob Steven | President, CEO, and Director | A | 104,516 | $0.00 | $0.00 |
| Mar 8, 2026 | Coleman Jon | EVP, Chief Commercial Officer | A | 43,897 | $0.00 | $0.00 |
| Mar 8, 2026 | Brown Michael Jon | EVP, Chief Legal Officer | F | 23,325 | $68.10 | $1.6M |
| Mar 8, 2026 | SAYER KEVIN R | Executive Chair | A | 32,749 | $0.00 | $0.00 |
| Mar 8, 2026 | SAYER KEVIN R | Executive Chair | F | 32,498 | $68.10 | $2.2M |
| Mar 8, 2026 | Sylvain Jereme M | EVP, Chief Financal Officer | A | 48,774 | $0.00 | $0.00 |
| Mar 8, 2026 | Sylvain Jereme M | EVP, Chief Financal Officer | F | 18,950 | $68.10 | $1.3M |
| Mar 8, 2026 | Brown Michael Jon | EVP, Chief Legal Officer | A | 39,019 | $0.00 | $0.00 |
| Mar 8, 2026 | Stern Sadie | EVP, Chief HR Officer | A | 39,019 | $0.00 | $0.00 |
| Mar 8, 2026 | Stern Sadie | EVP, Chief HR Officer | F | 17,199 | $68.10 | $1.2M |
| Mar 8, 2026 | Leach Jacob Steven | President, CEO, and Director | F | 19,757 | $68.10 | $1.3M |
| Feb 26, 2026 | Osterloh Albert Frederick IV | Director | A | 7,061 | $0.00 | $0.00 |
| Feb 12, 2026 | Heller Bridgette P | Director | SELL | 1,012 | $68.01 | $68.8K |
| Jan 29, 2026 | Leach Jacob Steven | President, CEO, and Director | F | 3,058 | $73.36 | $224.3K |
| Jan 29, 2026 | Leach Jacob Steven | President, CEO, and Director | A | 8,310 | $0.00 | $0.00 |
| Jan 29, 2026 | Stern Sadie | EVP, Chief HR Officer | F | 2,656 | $73.36 | $194.8K |
| Jan 29, 2026 | Stern Sadie | EVP, Chief HR Officer | A | 7,123 | $0.00 | $0.00 |
| Jan 29, 2026 | Sylvain Jereme M | EVP, Chief Financal Officer | F | 2,652 | $73.36 | $194.6K |
| Jan 29, 2026 | Sylvain Jereme M | EVP, Chief Financal Officer | A | 7,123 | $0.00 | $0.00 |
| Jan 29, 2026 | Brown Michael Jon | EVP, Chief Legal Officer | F | 2,653 | $73.36 | $194.6K |
| Jan 29, 2026 | Brown Michael Jon | EVP, Chief Legal Officer | A | 7,123 | $0.00 | $0.00 |
| Jan 29, 2026 | SAYER KEVIN R | Executive Chair | F | 34,257 | $73.36 | $2.5M |
| Jan 29, 2026 | SAYER KEVIN R | Executive Chair | A | 71,218 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.3/10.
NEUTRAL
CLUSTER
2/10
Two DexCom insiders — Director Bridgette P. Heller and EVP/Chief Legal Officer Michael Jon Brown — e
May 19, 2026
NEUTRAL
DEFA14A
2/10
Dexcom, Inc. has filed a definitive proxy statement (DEFA14A) for its upcoming annual shareholder me
Apr 15, 2026
MIXED
INST-CLUSTER
6/10
Three major institutions reduced their positions in Dexcom (DXCM) by a combined $166.3M in Q4 2025,
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (86% buy). Based on 37 analysts: 15 strong buy, 17 buy, 4 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$81.64 mean target
+16.3% upside
Buy (1.43)
$64.00 Low
$112.00 High
| Metric | Value |
|---|---|
| Current Price | $70.22 |
| Target Low | $64.00 |
| Target Mean | $81.64 |
| Target Median | $80.00 |
| Target High | $112.00 |
| # Analysts | 25 |
| Recommendation | Buy (1.43) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.61 | $0.57 | $0.66 | 26.4% | +0.6% | 10↑ 4↓ | $1.3B | 11.5% | 20 |
| Next Q 2026-09-30 |
$0.67 | $0.62 | $0.70 | 10.1% | -0.6% | 8↑ 6↓ | $1.3B | 10.7% | 20 |
| Current FY 2026-12-31 |
$2.59 | $2.46 | $2.65 | 23.7% | +3.6% | 21↑ 1↓ | $5.2B | 12.1% | 24 |
| Next FY 2027-12-31 |
$3.05 | $2.79 | $3.27 | 18.0% | +1.8% | 16↑ 6↓ | $5.8B | 11.5% | 24 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.607 | |
| 7d ago | $0.606 | +0.001 |
| 30d ago | $0.603 | +0.004 |
| 60d ago | $0.602 | +0.004 |
| 90d ago | $0.602 | +0.004 |
12 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 18, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 18, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| May 18, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| May 4, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| May 1, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 1, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 1, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Mar 11, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 25, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 17, 2026 | Truist Securities | REITERATE | Buy | Buy |
| Feb 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 13, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Feb 13, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 13, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 12, 2026 | Barclays | DOWNGRADE | Equal-Weight | Underweight |
| Jan 9, 2026 | Bernstein | MAINTAIN | Outperform | Outperform |
| Dec 17, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Dec 11, 2025 | Citigroup | MAINTAIN | Buy | Buy |
| Dec 2, 2025 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Nov 25, 2025 | Evercore ISI Group | INITIATE | — | In-Line |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 15 | 17 | 4 | 1 | 0 | 86% | |
| Apr 1, 2026 | 15 | 17 | 4 | 1 | 0 | 86% | |
| Mar 1, 2026 | 15 | 16 | 5 | 1 | 0 | 84% | |
| Feb 1, 2026 | 15 | 16 | 5 | 1 | 0 | 84% | |
| Jan 1, 2026 | 16 | 16 | 5 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
3 members of Congress traded this stock: 2 buys, 1 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | DexCom Inc | May 13, 2026 (31d) |
| Feb 4, 2026 | Michael McCaul | R | HOUSE | SELL | $1,001 - $15,000 | DexCom Inc | Mar 12, 2026 (37d) |
| Jan 26, 2026 | John Boozman | R | SENATE | BUY | $1,001 - $15,000 | DexCom Inc | Feb 15, 2026 (21d) |
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
short_volume
Short Volume: DXCM — 56.0% short (1.0M / 1.8M)
Short: 1,018,705 | Exempt: 1,733 | TRF Vol: 1,818,909 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings_calendar
DXCM Q1 2026 Earnings Scheduled — 2026-04-30
Apr 27, 2026
dark_pool
Dark Pool: DXCM — 8.3M shares, 116,930 trades
Week starting 2026-04-27. Total ATS volume: 8,266,797 shares across 116,930 trades.
Apr 20, 2026
dark_pool
Dark Pool: DXCM — 4.2M shares, 75,235 trades
Week starting 2026-04-20. Total ATS volume: 4,175,901 shares across 75,235 trades.
Apr 13, 2026
dark_pool
Dark Pool: DXCM — 7.0M shares, 107,890 trades
Week starting 2026-04-13. Total ATS volume: 7,008,566 shares across 107,890 trades.
Apr 6, 2026
dark_pool
Dark Pool: DXCM — 3.9M shares, 71,105 trades
Week starting 2026-04-06. Total ATS volume: 3,876,748 shares across 71,105 trades.
Apr 1, 2026
short_volume
Short Volume: DXCM — 55.8% short (0.7M / 1.3M)
Short: 738,098 | Exempt: 0 | TRF Vol: 1,323,221 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
dark_pool
Dark Pool: DXCM — 3.7M shares, 72,402 trades
Week starting 2026-03-30. Total ATS volume: 3,655,709 shares across 72,402 trades.
Mar 24, 2026
short_interest
FTD: DXCM — 145,266 shares ($9.6M) failed to deliver
Settlement: 20260324, Price: $65.94, FTD Value: $9,578,840.04, DEXCOM, INC
Mar 23, 2026
short_interest
FTD: DXCM — 487,024 shares ($32.6M) failed to deliver
Settlement: 20260323, Price: $66.95, FTD Value: $32,606,256.8, DEXCOM, INC
Mar 23, 2026
dark_pool
Dark Pool: DXCM — 4.2M shares, 73,160 trades
Week starting 2026-03-23. Total ATS volume: 4,246,968 shares across 73,160 trades.
Mar 20, 2026
short_interest
FTD: DXCM — 172,907 shares ($11.6M) failed to deliver
Settlement: 20260320, Price: $67.27, FTD Value: $11,631,453.89, DEXCOM, INC
Mar 16, 2026
dark_pool
Dark Pool: DXCM — 4.5M shares, 88,674 trades
Week starting 2026-03-16. Total ATS volume: 4,486,277 shares across 88,674 trades.
Mar 12, 2026
short_interest
FTD: DXCM — 8,667 shares ($0.6M) failed to deliver
Settlement: 20260312, Price: $66.31, FTD Value: $574,708.77, DEXCOM, INC
Mar 9, 2026
dark_pool
Dark Pool: DXCM — 5.1M shares, 93,718 trades
Week starting 2026-03-09. Total ATS volume: 5,101,875 shares across 93,718 trades.